DDInter1763 DDInter100
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis which are grown in a chemically defined protein-free medium. It is considered one of the most likely agents to be used in a biological attack. There are currently 2 anthrax vaccines approved by the FDA: BioThrax in August 15, 2016 and CYFENDUS in July 20, 2023.[L47566, L47561] These vaccines are currently stored in the Strategic National Stockpile in preparation for an Anthrax terrorist attack or for pre-exposure prophylaxis of personnel going to specific arenas around the world.
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Temsirolimus {u} (Compound) upregulates {v} (Gene) PLA2G4A
PLA2G4A {u} (Gene) is bound by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Etoposide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Temsirolimus {u} (Compound) upregulates {v} (Gene) SNAP25
SNAP25 {u} (Gene) is upregulated by {v} (Compound) Epirubicin
Epirubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Temsirolimus {u} (Compound) upregulates {v} (Gene) PLA2G4A
PLA2G4A {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Upadacitinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ustekinumab
Ustekinumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Etanercept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Anthrax vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Temsirolimus (Compound) upregulates PLA2G4A (Gene) and PLA2G4A (Gene) is bound by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Temsirolimus (Compound) upregulates SNAP25 (Gene) and SNAP25 (Gene) is upregulated by Epirubicin (Compound) and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Temsirolimus (Compound) upregulates PLA2G4A (Gene) and PLA2G4A (Gene) is downregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine